Immunotech Laboratories, Inc. (IMMB) Research

Immunotech Laboratories, Inc. specializes in the development and market introduction of unique protein-based therapeutics. These innovative compounds are designed to treat significant health challenges such as human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), various forms of hepatitis, and other conditions impacting the immune system. Their principal product is ITV-1, an immune therapeutic vaccine. This specialized preparation, consisting of an irreversible pepsin fraction in suspension, is deployed in the treatment of HIV/AIDS and Hepatitis C, and also plays a role in regulating the body's immune responses. The company's main operations are conducted from its headquarters situated in Monrovia, California. Additionally, as of June 14, 2017, Immunotech Laboratories, Inc. operates as an owned subsidiary of Eco-Petroleum Solutions, Inc.

Open Immunotech Laboratories, Inc. (IMMB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.